The Chronic Spontaneous Urticaria Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The market size for Chronic Spontaneous Urticaria has seen a noticeable increase recently. The market, which was valued at $2.06 billion in 2024, is anticipated to increase to $2.23 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 8.6%.
The Chronic Spontaneous Urticaria (CSU) market is predicted to reach $3.08 billion by 2029, with a compound annual growth rate (CAGR) of 8.4%.
Download Your Free Sample of the 2025 Chronic Spontaneous Urticaria Market Report and Uncover Key Trends Now!The drivers in the chronic spontaneous urticaria market are:
• Improvement in diagnostic tools for chronic spontaneous urticaria
• The rise in awareness among healthcare, patient advocacy, and support groups
• Ongoing studies and clinical trials exploring new treatment methods
• An increase in healthcare expenditure.
The chronic spontaneous urticaria market covered in this report is segmented –
1) By Treatment: Medication, Phototherapy, Other Treatments
2) By Route Of Administration: Oral, Topical, Parenteral, Other Routes Of Administration
3) By Diagnosis: Physical Examination, Blood Test, Allergy Test, Other Diagnosis
4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users
The trends in the chronic spontaneous urticaria market are:
• Technological innovations and advancements in biological therapies are shaping the chronic spontaneous urticaria market.
• Personalized medicine is an emerging trend that could have a significant impact on the industry.
• The rise of telemedicine and digital health technologies are also influencing the marketplace.
• Advanced diagnostic tools, artificial intelligence, machine learning, and increasing drug approvals and launches are the other notable trends.
The major players in the chronic spontaneous urticaria market are:
The leading players and top competitors in the chronic spontaneous urticaria market encompass the following companies:
• F. Hoffmann-La Roche AG
North America was the largest region in the chronic spontaneous urticaria market in 2023